source
- Scribe’s Benjamin Oakes on a rare IPO and bringing CRISPR to the massesThe CEO spoke with BioPharma Dive about convincing investors to buy into the first gene editing IPO in more than two years.BioPharma Dive · 6h ago↗ source
- Latigo Biotherapeutics raises $345.6M in IPO to fund non-opioid pain drug pipelineLatigo Biotherapeutics, a Los Angeles-based biotech focused on non-opioid ion-channel-blocking pain therapies, completed an initial public offering on Thursday. The company sold 19.2 million share…